NASDAQ:VRCAVerrica Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.60 -0.24 (-3.51 %) (As of 08/7/2020 02:50 PM ET) Add Compare Share Today's Range$6.60Now: $6.60▼$6.9050-Day Range$6.48MA: $9.78▼$15.1252-Week Range$6.13Now: $6.60▼$18.67Volume4,640 shsAverage Volume228,523 shsMarket Capitalization$170.35 millionP/E RatioN/ADividend YieldN/ABeta2.07 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Verrica Pharmaceuticals Inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the United States. The company's lead product candidate include VP-102 that is in phase III clinical trial for the treatment of molluscum contagiosum; in phase II clinical trial for the treatment of common warts; and completed phase I clinical trial for the treatment of Genital warts. It is also developing cantharidin-based product candidate, VP-103 for the treatment of plantar warts. The company was founded in 2013 and is headquartered in West Chester, Pennsylvania.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingVerrica Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.00, Verrica Pharmaceuticals has a potential upside of 123.9% from its current price of $6.70.Amount of Analyst CoverageVerrica Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.3 Community Rank Outperform VotesVerrica Pharmaceuticals has received 119 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVerrica Pharmaceuticals has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentVerrica Pharmaceuticals has received 54.41% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Verrica Pharmaceuticals and other stocks. Vote “Outperform” if you believe VRCA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRCA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVerrica Pharmaceuticals does not currently pay a dividend.Dividend GrowthVerrica Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders40.20% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.23% of the stock of Verrica Pharmaceuticals is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verrica Pharmaceuticals are expected to decrease in the coming year, from ($1.70) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verrica Pharmaceuticals is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verrica Pharmaceuticals is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerrica Pharmaceuticals has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.52 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRCA Previous Symbol CUSIPN/A CIKN/A Webwww.verrica.com Phone484-453-3300Debt Debt-to-Equity Ratio0.61 Current Ratio27.45 Quick Ratio27.45Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.52 per share Price / Book2.62Profitability EPS (Most Recent Fiscal Year)($1.13) Net Income$-28,210,000.00 Net MarginsN/A Return on Equity-51.16% Return on Assets-41.38%Miscellaneous Employees16 Outstanding Shares25,810,000Market Cap$170.35 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $6.60 -0.24 (-3.51 %) (As of 08/7/2020 02:50 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VRCA News and Ratings via Email Sign-up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Verrica Pharmaceuticals (NASDAQ:VRCA) Frequently Asked Questions How has Verrica Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Verrica Pharmaceuticals' stock was trading at $10.52 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VRCA shares have decreased by 37.3% and is now trading at $6.60. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Verrica Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verrica Pharmaceuticals. When is Verrica Pharmaceuticals' next earnings date? Verrica Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Verrica Pharmaceuticals. How were Verrica Pharmaceuticals' earnings last quarter? Verrica Pharmaceuticals Inc (NASDAQ:VRCA) released its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.07. View Verrica Pharmaceuticals' earnings history. What price target have analysts set for VRCA? 5 brokers have issued 1-year price targets for Verrica Pharmaceuticals' stock. Their forecasts range from $10.00 to $18.00. On average, they anticipate Verrica Pharmaceuticals' stock price to reach $15.00 in the next year. This suggests a possible upside of 127.3% from the stock's current price. View analysts' price targets for Verrica Pharmaceuticals. Has Verrica Pharmaceuticals been receiving favorable news coverage? Media coverage about VRCA stock has been trending positive on Friday, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Verrica Pharmaceuticals earned a news impact score of 2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Verrica Pharmaceuticals. Are investors shorting Verrica Pharmaceuticals? Verrica Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totaling 1,040,000 shares, an increase of 25.2% from the July 15th total of 830,400 shares. Based on an average trading volume of 95,300 shares, the short-interest ratio is presently 10.9 days. Approximately 8.1% of the company's stock are short sold. View Verrica Pharmaceuticals' Current Options Chain. Who are some of Verrica Pharmaceuticals' key competitors? Some companies that are related to Verrica Pharmaceuticals include Tricida (TCDA), Kadmon (KDMN), Frequency Therapeutics (FREQ), Trillium Therapeutics (TRIL), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), G1 Therapeutics (GTHX), Aprea Therapeutics (APRE), Mirum Pharmaceuticals (MIRM), Stemline Therapeutics (STML), Collegium Pharmaceutical (COLL), Basilea Pharmaceutica (BPMUF), Applied Therapeutics (APLT), Syndax Pharmaceuticals (SNDX) and Cue Biopharma (CUE). View all competitors. What other stocks do shareholders of Verrica Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include AbbVie (ABBV), Gilead Sciences (GILD), Aurora Cannabis (ACB), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Pfizer (PFE), Progenics Pharmaceuticals (PGNX), Exxon Mobil (XOM), Allergan (AGN) and Agile Therapeutics (AGRX). Who are Verrica Pharmaceuticals' key executives? Verrica Pharmaceuticals' management team includes the following people: Mr. Ted White, Pres, CEO & Director (Age 54)Mr. Chris Degnan, Chief Financial Officer (Age 39)Mr. Joe Bonaccorso, Chief Commercial Officer (Age 55)Dr. Patrick Burnett M.D., Ph.D., Chief Medical Officer (Age 47)Christopher G. Hayes, Sec. When did Verrica Pharmaceuticals IPO? (VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO. What is Verrica Pharmaceuticals' stock symbol? Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA." Who are Verrica Pharmaceuticals' major shareholders? Verrica Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Kornitzer Capital Management Inc. KS (1.90%), Creative Planning (0.08%), Spouting Rock Asset Management LLC (0.06%) and UBS Group AG (0.03%). Company insiders that own Verrica Pharmaceuticals stock include Linda Palczuk, Matt Davidson, Paul B Manning, Sean Stalfort and Ted White. View institutional ownership trends for Verrica Pharmaceuticals. Which major investors are selling Verrica Pharmaceuticals stock? VRCA stock was sold by a variety of institutional investors in the last quarter, including Spouting Rock Asset Management LLC, and UBS Group AG. View insider buying and selling activity for Verrica Pharmaceuticals. Which major investors are buying Verrica Pharmaceuticals stock? VRCA stock was bought by a variety of institutional investors in the last quarter, including Creative Planning, and Kornitzer Capital Management Inc. KS. Company insiders that have bought Verrica Pharmaceuticals stock in the last two years include Linda Palczuk, Paul B Manning, Sean Stalfort, and Ted White. View insider buying and selling activity for Verrica Pharmaceuticals. How do I buy shares of Verrica Pharmaceuticals? Shares of VRCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Verrica Pharmaceuticals' stock price today? One share of VRCA stock can currently be purchased for approximately $6.60. How big of a company is Verrica Pharmaceuticals? Verrica Pharmaceuticals has a market capitalization of $170.35 million. The company earns $-28,210,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Verrica Pharmaceuticals employs 16 workers across the globe. What is Verrica Pharmaceuticals' official website? The official website for Verrica Pharmaceuticals is www.verrica.com. How can I contact Verrica Pharmaceuticals? Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The company can be reached via phone at 484-453-3300 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
